首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >Intraoperative intrasac thrombin injection to prevent type II endoleak after endovascular abdominal aortic aneurysm repair.
【24h】

Intraoperative intrasac thrombin injection to prevent type II endoleak after endovascular abdominal aortic aneurysm repair.

机译:术中注射囊内凝血酶可防止血管内腹主动脉瘤修复后发生II型内漏。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: To report a prospective, nonrandomized pilot study to determine whether fibrin glue aneurysm sac embolization at the time of endovascular aneurysm repair (EVAR) is a safe and effective procedure to primarily prevent type II endoleaks. METHODS: Between June 2003 and December 2005, 84 consecutive patients (79 men; mean age 73.8+/-7.8 years, range 64-86) with degenerative infrarenal abdominal aortic aneurysm underwent EVAR with bifurcated stent-grafts and fibrin glue injection into the aneurysm sac at the conclusion of the endovascular procedure. A total of 424 imaging studies and 348 visits were recorded during the study period and reviewed. RESULTS: Selective catheterization of the aneurysm sac and fibrin glue injection immediately after initial stent-graft deployment was successful in 83 (99%) of 84 cases; there was one failure to access the excluded aneurysm sac due to severe iliac artery calcification. The estimated primary and assisted clinical success rates at 2 years were 91.3% and 98.8%,respectively, but the major findings were the low rate of delayed type II endoleak (2.4%) and the statistically significant decrease in the maximum transverse aneurysm diameter (50.40+/-6.70 versus 42.03+/-6.50 mm, p = 0.0001) at follow-up. In addition, of 31 patients available for 24-month follow-up, 14 (45.2%) patients showed a reduction in maximum transverse aneurysm diameter by >or=5 mm; 16 (51.6%) patients had no significant changes, whereas only 1 patient showed a >5-mm enlargement. CONCLUSION: This clot engineering approach to aneurysm sac embolization at the time of endografting appears to be safe and may spare the patient a repeated catheter-based intervention or surgical procedure.
机译:目的:报告一项前瞻性,非随机的前瞻性研究,以确定在血管内动脉瘤修复(EVAR)时纤维蛋白胶动脉瘤囊栓塞是否是主要预防II型内漏的安全有效方法。方法:2003年6月至2005年12月,连续84例退行性肾下腹主动脉瘤患者(79名男性,平均年龄73.8 +/- 7.8岁,范围64-86)接受了EVAR,分叉的支架移植物和纤维蛋白胶注入动脉瘤囊腔内手术结束。在研究期间共记录并审查了424项影像学研究和348次就诊。结果:84例患者中,有83例(99%)在初始支架置入后立即选择性行动脉瘤囊和纤维蛋白胶注射。由于严重的动脉钙化,无法进入排除的动脉瘤囊。估计在2年时的主要和辅助临床成功率分别为91.3%和98.8%,但主要发现是延迟的II型内渗漏发生率低(2.4%)和最大横向动脉瘤直径的统计学显着性降低(50.40)。 +/- 6.70 vs. 42.03 +/- 6.50 mm,p = 0.0001)。此外,在31位可进行24个月随访的患者中,有14位(45.2%)患者的最大横向动脉瘤直径减少了>或= 5 mm。 16例(51.6%)患者无明显变化,而只有1例患者显示> 5 mm肿块。结论:这种在移植内膜时采用血栓工程方法进行动脉瘤囊栓塞的方法似乎是安全的,并且可以使患者免于反复进行基于导管的干预或外科手术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号